Filing Details

Accession Number:
0001104659-19-041021
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-07-18 19:04:22
Reporting Period:
2019-07-17
Accepted Time:
2019-07-18 19:04:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1481512 Ra Pharmaceuticals Inc. RARX Pharmaceutical Preparations (2834) 262908274
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1688199 Simon Read C/O Ra Pharmaceuticals, Inc.
87 Cambridgepark Drive
Cambridge MA 02140
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-07-17 10,000 $2.87 16,234 No 4 M Direct
Common Stock Disposition 2019-07-17 10,000 $32.95 6,234 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to buy) Disposition 2019-07-17 10,000 $0.00 10,000 $2.87
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
96,142 2026-06-16 No 4 M Direct
Footnotes
  1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019.
  2. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $32.57 to $33.43. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. These stock options vest over four (4) years beginning on April 4, 2016, at a rate of twenty-five percent (25%) after 12 months, and in thirty-six (36) equal monthly installments thereafter.